UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 112.

Judd, A; et al; Ledergerber, B (2017). Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. HIV Medicine, 18(3):171-180.

Shepherd, L; Borges, Áh; Ledergerber, B; Domingo, P; Castagna, A; Rockstroh, J; Knysz, B; Tomazic, J; Karpov, I; Kirk, O; Lundgren, J; Mocroft, A (2016). Infection-related and -unrelated malignancies, HIV and the aging population. HIV Medicine, 17(8):590-600.

Schaerer, V; Haubitz, S; Kovari, H; Ledergerber, B; Ambrosioni, J; Cavassini, M; Stoeckle, M; Schmid, P; Decosterd, L; Aouri, M; Böni, J; Günthard, H F; Furrer, H; Metzner, K J; Fehr, J; Rauch, A (2015). Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. HIV Medicine, 16(10):599-607.

Matter-Walstra, K W; Greiner, M; Cusini, A; Schiesser, M; Ledergerber, B; Fehr, T; Mueller, N J (2015). Stringent adherence to a cytomegalovirus-prevention protocol is associated with reduced overall costs in the first 6 months after kidney transplantation. Transplant Infectious Disease, 17(3):342-349.

Vingerhoets, J; Calvez, V; Flandre, P; Marcelin, A G; Ceccherini-Silberstein, F; Perno, C F; Mercedes Santoro, M; Bateson, R; Nelson, M; Cozzi-Lepri, A; Grarup, J; Lundgren, J; Incardona, F; Kaiser, R; Sonnerborg, A; Clotet, B; Paredes, R; Günthard, Hf; Ledergerber, B; Hoogstoel, A; Nijs, S; Tambuyzer, L; Lavreys, L; Opsomer, M; Etravirine Cohort Study Group (2015). Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. HIV Medicine, 16(5):297-306.

Schäfer, J; Young, J; Bernasconi, E; Ledergerber, B; Nicca, D; Calmy, A; Cavassini, M; Furrer, H; Battegay, M; Bucher, H C; Swiss HIV Cohort Study (2015). Predicting smoking cessation and its relapse in HIV-infected patients: the Swiss HIV Cohort Study. HIV Medicine, 16(1):3-14.

Weber, R; Huber, M; Battegay, M; Stähelin, C; Castro Batanjer, E; Calmy, A; Bregenzer, A; Bernasconi, E; Schoeni-Affolter, F; Ledergerber, B (2015). Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort Study. HIV Medicine, 16(3):137-151.

Arab-Alameddine, M; Lubomirov, R; Fayet-Mello, A; Aouri, M; Rotger, M; Buclin, T; Widmer, N; Gatri, M; Ledergerber, B; Rentsch, K; Cavassini, M; Panchaud, A; Guidi, M; Telenti, A; Décosterd, L A; Csajka, C (2014). Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 69(9):2489-2498.

Kohler, Ines; Scherrer, A U; Zagordi, O; Bianchi, M; Wyrzucki, A; Steck, M; Ledergerber, B; Gunthard, H F; Hangartner, L (2014). Prevalence and predictors for homo- and heterosubtypic antibodies against influenza a virus. Clinical Infectious Diseases, 59(10):1386-1393.

Kouyos, R D; Rauch, A; Braun, D L; Yang, W-L; Böni, J; Yerly, S; Klimkait, T; Aubert, V; Shah, C; Kovari, H; Calmy, A; Cavassini, M; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Gunthard, H F (2014). Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. Journal of Infectious Diseases, 210(10):1555-1561.

Braun, D L; Rauch, A; Durisch, N; Eberhard, N; Anagnostopoulos, A; Ledergerber, B; Metzner, K J; Böni, J; Weber, R; Fehr, J (2014). Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients. HIV Medicine, 15:625-630.

Braun, D l; Rauch, A; Durisch, N; Eberhard, N; Anagnostopoulos, A; Ledergerber, B; Metzner, K J; Boni, J; Weber, R; Fehr, J (2014). Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients. Neurobehavioral HIV Medicine, 15(10):625-630.

Hasse, B; Iff, M; Ledergerber, B; Calmy, A; Schmid, P; Hauser, C; Cavassini, M; Bernasconi, E; Marzolini, C; Tarr, P E; Aubert, V; Barth, J; Battegay, M; Bernasconi, E; Boni, J; Bucher, H C; Burton-Jeangros, C; Calmy, A; Cavassini, M; Egger, M; Elzi, L; Fehr, J; Fellay, J; Furrer, H; Fux, C A; Gorgievski, M; Gunthard, H; Haerry, D; Hasse, B; Hirsch, H H; Hosli, I; Kahlert, C; Kaiser, L; Keiser, O; Klimkait, T; Kouyos, R; Kovari, H; Ledergerber, B; Martinetti, G; Martinez de Tejada, B; Metzner, K; Muller, N; Nadal, D; Pantaleo, G; Rauch, A; Regenass, S; Rickenbach, M; Rudin, C; Schoni-Affolter, F; Schmid, P; Schultze, D; Schupbach, J; Speck, R; Staehelin, C; Tarr, P; Telenti, A; Trkola, A; Vernazza, P; Weber, R; Yerly, S (2014). Obesity trends and body mass index changes after starting antiretroviral treatment: The Swiss HIV cohort study. Open Forum Infectious Diseases, 1(2):ofu040.

Weber, R; Ruppik, M; Rickenbach, M; Spoerri, A; Furrer, H; Battegay, M; Cavassini, M; Calmy, A; Bernasconi, E; Schmid, P; Flepp, M; Kowalska, J; Ledergerber, B; Schmid, P; Schultze, D; Schöni-Affolter, F; Schüpbach, J; Speck, R; Taffé, P; Tarr, P; Telenti, A; Trkola, A; Vernazza, P; Weber, R; Yerly, S (2013). Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Medicine, 14(4):195-207.

Achermann, Y; Eigenmann, K; Ledergerber, B; Derksen, L; Rafeiner, P; Clauss, M; Nüesch, R; Zellweger, C; Vogt, M; Zimmerli, W (2013). Factors associated with rifampin resistance in staphylococcal periprosthetic joint infections (PJI): a matched case–control study. Infection, 41(2):431-437.

Cusini, A; Vernazza, P L; Yerly, S; Decosterd, L A; Ledergerber, B; Fux, C A; Rohrbach, J; Widmer, N; Hirschel, B; Gaudenz, R; Cavassini, M; Klimkait, Th; Zenger, F; Gutmann, C; Opravil, M; Günthard, H F (2013). Higher CNS Penetration-Effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. Journal of Acquired Immune Deficiency Syndromes, 62(1):28-35.

Ledergerber, B; Costagliola, D; Lodwick, R; Torti, C; van Sighem, A; Podzamczer, D; Mocroft, A; Dorrucci, M; Masquelier, B; Günthard, H F; de Luca, A; Michalik, C (2013). Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 207(5):759-767.

Grint, D; Peters, L; Reekie, J; Soriano, V; Kirk, O; Knysz, B; Suetnov, O; Lazzarin, A; Ledergerber, B; Rockstroh, J K; Mocroft, A (2013). Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. HIV Medicine, 14(6):370-378.

Greiner, M; Cusini, A; Ruesch, M; Schiesser, M; Ledergerber, B; Fehr, T; Mueller, N J (2012). A stringent preemptive protocol reduces cytomegalovirus disease in the first 6 months after kidney transplantation. Infection, 40(6):669-675.

Savaria, F; Zbinden, R; Wüst, J; Burnens, A; Ledergerber, B; Weber, R; Kovari, H (2012). Antibiotikaresistenzen von E.coli in Urinproben: Prävalenzdaten dreier Laboratorien im Raum Zürich von 1985 bis 2010. Praxis, 101(9):573-579.

Mocroft, A; Phillips, A; Gatell, J; Horban, A; Ledergerber, B; Zilmer, K; Jevtovic, D; Maltez, F; Kirk, O; Lundgren, J (2012). CD4 count and viral load specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. Journal of the International Aids Society, 15(6):18191.

von Wyl, V; Yerly, S; Böni, J; Shah, C; Cellerai, C; Klimkait, T; Battegay, M; Bernasconi, E; Cavassini, M; Furrer, H; Hirschel, B; Vernazza, P L; Ledergerber, B; Günthard, H F (2012). Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clinical Infectious Diseases, 54(1):131-140.

Herbeck, J T; Müller, V; Maust, B S; Ledergerber, B; Torti, C; Di Giambenedetto, S; Gras, L; Günthard, H F; Jacobson, L P; Mullins, J I; Gottlieb, G S (2012). Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission. AIDS, 26(2):193-205.

Kowalska, J D; Reekie, J; Mocroft, A; Reiss, P; Ledergerber, B; Gatell, J; D'Arminio Monforte, A; Phillips, A; Lundgren, J D; Kirk, O (2012). Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. AIDS, 26(3):315-323.

Nemeth, J; Ledergerber, B; Preiswerk, B; Nobile, A; Karrer, S; Ruef, C; Kuster, S P (2012). Multidrug-resistant bacteria in travellers hospitalized abroad: prevalence, characteristics, and influence on clinical outcome. Journal of Hospital Infection, 82(4):254-259.

Huber, M; Ledergerber, B; Sauter, R; Young, J; Fehr, J; Cusini, A; Battegay, M; Calmy, A; Orasch, C; Nicca, D; Bernasconi, E; Jaccard, R; Held, L; Weber, R (2012). Outcome of smoking cessation counselling of HIV-positive persons by HIV care physicians. HIV medicine, 13(7):387-397.

Keiser, O; Spycher, B; Rauch, A; Calmy, A; Cavassini, M; Glass, T R; Nicca, D; Ledergerber, B; Egger, M (2012). Outcomes of antiretroviral therapy in the Swiss HIV Cohort Study: Latent class analysis. AIDS and Behavior, 16(2):245-255.

Thierfelder, C; Weber, R; Elzi, L; Furrer, H; Cavassini, M; Calmy, A; Bernasconi, E; Gutmann, C; Ledergerber, B (2012). Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort Study. HIV Medicine, 13(2):118-126.

Scherrer, A U; von Wyl, V; Götte, M; Klimkait, T; Cellerai, C; Yerly, S; Böni, J; Held, L; Ledergerber, B; Günthard, H F (2012). Polymorphic mutations associated with the emergence of the multi-nucleoside/tide resistance mutations 69 insertion and Q151M. Journal of Acquired Immune Deficiency Syndromes, 59(2):105-112.

Braun, J; Held, L; Ledergerber, B (2012). Predictive cross-validation for the choice of linear mixed-effects models with application to data from the Swiss HIV Cohort Study. Biometrics, 68(1):53-61.

Taylor, N; Grabmeier-Pfistershammer, K; Oberkofler, H; Egle, A; Rieger, A; Ledergerber, B (2012). Upgraded Cobas TaqMan version 2: hidden consequences at cohort level. Journal of the International Aids Society, 15(6):18207.

Reekie, J; Reiss, P; Ledergerber, B; Sedlacek, D; Parczewski, M; Gatell, J; Katlama, C; Fätkenheuer, G; Lundgren, J D; Mocroft, A (2011). A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. HIV Medicine, 12(5):259-268.

Kowalska, J D; Mocroft, A; Ledergerber, B; Florence, E; Ristola, M; Begovac, J; Sambatakou, H; Pedersen, C; Lundgren, J D; Kirk, O (2011). A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study. HIV Clinical Trials, 12(2):109-117.

Kouyos, R D; von Wyl, V; Yerly, S; Böni, J; Rieder, P; Joos, B; Taffé, P; Shah, C; Bürgisser, P; Klimkait, T; Weber, R; Hirschel, B; Cavassini, M; Rauch, A; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Bonhoeffer, S; Günthard, H F (2011). Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clinical Infectious Diseases, 52(4):532-539.

Røysland, K; Gran, J M; Ledergerber, B; von Wyl, V; Young, J; Aalen, O O (2011). Analyzing direct and indirect effects of treatment using dynamic path analysis applied to data from the Swiss HIV Cohort Study. Statistics in Medicine, 30(24):2947-2958.

Lubomirov, R; Colombo, S; di Iulio, J; Ledergerber, B; Martinez, R; Cavassini, M; Hirschel, B; Bernasconi, E; Elzi, L; Vernazza, P; Furrer, H; Günthard, H F; Telenti, A (2011). Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. Journal of Infectious Diseases, 203(2):246-257.

Baker, J V; Neuhaus, J; Duprez, D; Kuller, L H; Tracy, R; Belloso, W H; De Wit, S; Drummond, F; Lane, H C; Ledergerber, B; Lundgren, J; Nixon, D E; Paton, N I; Neaton, J D (2011). Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. JAIDS Journal of Acquired Immune Deficiency Syndromes, 56(1):36-43.

Schöni-Affolter, F; Keiser, O; Mwango, A; Stringer, J; Ledergerber, B; Mulenga, L; Bucher, H C; Westfall, A O; Calmy, A; Boulle, A; Chintu, N; Egger, M; Chi, B H (2011). Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: The effect of the competing risk of death in Zambia and Switzerland. PLoS ONE, 6(12):e27919.

Scherrer, A U; Ledergerber, B; von Wyl, V; Böni, J; Yerly, S; Klimkait, T; Bürgisser, P; Rauch, A; Hirschel, B; Cavassini, M; Elzi, L; Vernazza, P L; Bernasconi, E; Held, L; Günthard, H F (2011). Improved virological outcome in white patients infected with HIV-1 non-B subtypes compared to subtype B. Clinical Infectious Diseases, 53(11):1143-1152.

Giner, A M; Kuster, S P; Zbinden, R; Ruef, C; Ledergerber, B; Weber, R (2011). Initial management of and outcome in patients with pneumococcal bacteremia: a retrospective study at a Swiss university hospital, 2003-2009. Infection, 39(6):519-526.

Hasse, B; Ledergerber, B; Furrer, H; Battegay, M; Hirschel, B; Cavassini, M; Bertisch, B; Bernasconi, E; Weber, R (2011). Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clinical Infectious Diseases, 53(11):1130-1139.

Ortiz, M; Poloni, E S; Furrer, H; Kovari, H; Martinez, R; Arnedo, M; Elzi, L; Bernasconi, E; Vernazza, P; Hirschel, B; Cavassini, M; Ledergerber, B; Günthard, H F; Telenti, A; Tarr, P E (2011). No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy. Journal of Infectious Diseases, 203(5):620-624.

Young, J; Klein, M B; Ledergerber, B (2011). Noncirrhotic portal hypertension and didanosine: a re-analysis. Clinical Infectious Diseases, 52(1):154-155.

Scherrer, A U; von Wyl, V; Joos, B; Klimkait, T; Bürgisser, P; Yerly, S; Böni, J; Ledergerber, B; Günthard, H F (2011). Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study. Journal of Infectious Diseases, 203(6):791-797.

Haas, A; Zimmermann, K; Graw, F; Slack, E; Rusert, P; Ledergerber, B; Bossart, W; Weber, R; Thurnheer, M C; Battegay, M; Hirschel, B; Vernazza, P; Patuto, N; Macpherson, A J; Günthard, H F; Oxenius, A (2011). Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. Gut, 60(11):1506-1519.

von Wyl, V; Kouyos, R D; Yerly, S; Böni, J; Shah, C; Bürgisser, P; Klimkait, T; Weber, R; Hirschel, B; Cavassini, M; Staehelin, C; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Bonhoeffer, S; Günthard, H F (2011). The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. Journal of Infectious Diseases, 204(7):1095-1103.

Ledergerber, B; Cavassini, M; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B; Furrer, H; Rickenbach, M; Weber, R (2011). Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV Medicine, 12(5):279-288.

Scherrer, A U; von Wyl, V; Böni, J; Yerly, S; Klimkait, T; Bürgisser, P; Garzoni, C; Hirschel, B; Cavassini, M; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Günthard, H F (2011). Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. JAIDS Journal of Acquired Immune Deficiency Syndromes, 57(1):24-31.

Nicoletti, J; Kuster, S; Sulser, T; Zbinden, R; Ruef, C; Ledergerber, B; Weber, R (2010). Risk factors for urinary tract infections due to ciprofloxacin-resistant Escherichia coli in a tertiary care urology department in Switzerland. Swiss Medical Weekly, (140):w13059.

Scherrer, A U; von Wyl, V; Fux, C A; Opravil, M; Bucher, H C; Fayet, A; Decosterd, L A; Hirschel, B; Khanlari, B; Yerly, S; Klimkait, T; Furrer, H; Ledergerber, B; Günthard, H F (2010). Implementation of Raltegravir in routine clinical practice: Selection criteria for choosing this drug, virologic response rates, and characteristics of failures. JAIDS Journal of Acquired Immune Deficiency Syndromes, 53(4):464-471.

Gianella, S; Haeberli, L; Joos, B; Ledergerber, B; Wüthrich, R P; Weber, R; Kuster, H; Hauser, P M; Fehr, T; Mueller, N J (2010). Molecular evidence of interhuman transmission in an outbreak of Pneumocystis jirovecii pneumonia among renal transplant recipients. Transplant Infectious Disease, 12(1):1-10.

Colombo, C; Ledergerber, B; Zysset, F; Francioli, P; Cavassini, M; Ruef, C (2010). HIV-, HBV und HCV-Exposition im medizinischen Bereich in der Schweiz von 2001 bis Ende Juni 2008. BAG Bulletin, (3):36-42.

Gran, J M; Røysland, K; Wolbers, M; Didelez, V; Sterne, J A C; Ledergerber, B; Furrer, H; von Wyl, V; Aalen, O O (2010). A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study. Statistics in Medicine, 29(26):2757-2768.

Lubomirov, R; di Iulio, J; Fayet, A; Colombo, S; Martinez, R; Marzolini, C; Furrer, H; Vernazza, P; Calmy, A; Cavassini, M; Ledergerber, B; Rentsch, K; Descombes, P; Buclin, Thierry; Decosterd, L A; Csajka, C; Telenti, A (2010). ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenetics and Genomics, 20(4):217-230.

Franceschi, S; Lise, M; Clifford, G M; Rickenbach, M; Levi, F; Maspoli, M; Bouchardy, C; Dehler, S; Jundt, G; Ess, S; Bordoni, A; Konzelmann, I; Frick, H; Dal Maso, L; Elzi, L; Furrer, H; Calmy, A; Cavassini, M; Ledergerber, B; Keiser, O; Swiss HIV Cohort Study (2010). Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. British Journal of Cancer, 103(3):416-422.

Schoeni-Affolter, F; Ledergerber, B; Rickenbach, M; Rudin, C; Günthard, H F; Telenti, A; Furrer, H; Yerly, S; Francioli, P (2010). Cohort profile: the Swiss HIV Cohort study. International Journal of Epidemiology, 39(5):1179-1189.

Lodwick, R K; Sabin, C A; Porter, K; Ledergerber, B; van Sighem, A; Cozzi-Lepri, A; Khaykin, P; Mocroft, A; Jacobson, L; De Wit, S; Obel, N; Castagna, A; Wasmuth, J C; Gill, J; Klein, M B; Gange, S; Riera, M; Mussini, C; Gutiérrez, F; Touloumi, G; Carrieri, P; Guest, J L; Brockmeyer, N H; Phillips, A N (2010). Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet, 376(9738):340-345.

Cusini, A; Rampini, S K; Bansal, V; Ledergerber, B; Kuster, S P; Ruef, C; Weber, R (2010). Different patterns of inappropriate antimicrobial use in surgical and medical units at a tertiary care hospital in Switzerland: a prevalence survey. PLoS ONE, 5(11):e14011.

von Wyl, V; Ehteshami, M; Symons, J; Bürgisser, P; Nijhuis, M; Demeter, L M; Yerly, S; Böni, J; Klimkait, T; Schuurman, R; Ledergerber, B; Götte, M; Günthard, H F (2010). Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase. Journal of Infectious Diseases, 201(7):1054-1062.

Mocroft, A; Phillips, A N; Ledergerber, B; Smith, C; Bogner, J R; Lacombe, K; Wiercinska-Drapalo, A; Reiss, P; Kirk, O; Lundgren, J D (2010). Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. Antiviral Therapy, 15(4):563-570.

Mocroft, A; Kirk, O; Reiss, P; De Wit, S; Sedlacek, D; Beniowski, M; Gatell, J; Phillips, A N; Ledergerber, B; Lundgren, J D (2010). Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS, 24(11):1667-1678.

Hasse, B; Ledergerber, B; Hirschel, B; Vernazza, P; Glass, T R; Jeannin, A; Evison, J M; Elzi, L; Cavassini, M; Bernasconi, E; Nicca, D; Weber, R (2010). Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. Clinical Infectious Diseases, 51(11):1314-1322.

Weber, R; Sabin, C; Reiss, P; De Wit, S; Worm, S W; Law, M; Dabis, F; D'Arminio Monforte, A; Fontas, E; El-Sadr, W; Kirk, O; Rickenbach, M; Phillips, A; Ledergerber, B; Lundgren, J (2010). HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D cohort study. Antiviral Therapy, 15(8):1077-1086.

von Wyl, V; Ehteshami, M; Demeter, L M; Bürgisser, P; Nijhuis, M; Symons, J; Yerly, S; Böni, J; Klimkait, T; Schuurman, R; Ledergerber, B; Götte, M; Günthard, H F (2010). HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy. Clinical Infectious Diseases, 51(5):620-628.

Mueller, N J; Fux, C A; Ledergerber, B; Elzi, L; Schmid, P; Dang, T; Magenta, L; Calmy, A; Vergopoulos, A; Bischoff-Ferrari, H A (2010). High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS, 24(8):1127-1134.

Reekie, J; Mocroft, A; Ledergerber, B; Beniowski, M; Clotet, B; van Lunzen, J; Chiesi, A; Pradier, C; Machala, L; Lundgren, J D (2010). History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change. HIV Medicine, 11(7):469-478.

Rotger, M; Gsponer, T; Martinez, R; Taffé, P; Elzi, L; Vernazza, P; Cavassini, M; Bernasconi, E; Hirschel, B; Furrer, H; Weber, R; Ledergerber, B; Egger, M; Telenti, A; Tarr, P E; Swiss HIV Cohort Study (2010). Impact of single nucleotide polymorphisms and of clinical risk factors on new‐onset diabetes mellitus in HIV‐infected individuals. Clinical Infectious Diseases, 51(9):1090-1098.

Kovari, H; Ledergerber, B; Battegay, M; Rauch, A; Hirschel, B; Foguena, A K; Vernazza, P; Bernasconi, E; Mueller, N J; Weber, R (2010). Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. Clinical Infectious Diseases, 50(4):502-511.

Kouyos, R D; von Wyl, V; Yerly, S; Böni, J; Taffé, P; Shah, C; Bürgisser, P; Klimkait, T; Weber, R; Hirschel, B; Cavassini, M; Furrer, H; Battegay, M; Vernazza, P L; Bernasconi, E; Rickenbach, M; Ledergerber, B; Bonhoeffer, S; Günthard, H F (2010). Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. Journal of Infectious Diseases, 201(10):1488-1497.

Marzolini, C; Elzi, L; Gibbons, S; Weber, R; Fux, C; Furrer, H; Chave, J P; Cavassini, M; Bernasconi, E; Calmy, A; Vernazza, P; Khoo, S; Ledergerber, B; Back, D; Battegay, M (2010). Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antiviral Therapy, 15(3):413-423.

Kovari, H; Ledergerber, B; Weber, R (2010). Reply to Chang and Garcia-Pagan. Clinical Infectious Diseases, 50(1):128-129.

Kuster, S P; Hasse, B; Huebner, V; Bansal, V; Zbinden, R; Ruef, C; Ledergerber, B; Weber, R (2010). Risks factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care university hospital in Switzerland. Infection, 38(1):33-40.

Mocroft, A; Reiss, P; Gasiorowski, J; Ledergerber, B; Kowalska, J; Chiesi, A; Gatell, J; Rakhmanova, A; Johnson, M; Kirk, O; Lundgren, J (2010). Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. Journal of Acquired Immune Deficiency Syndrome, 55(2):262-270.

Kovari, H; Ledergerber, B; Weber, R (2010). Should HIV-infected patients with unexplained chronic liver enzyme elevations be tested for hepatitis E virus? Letter Reply. Clinical Infectious Diseases, 50(11):1546-1547.

Elzi, L; Marzolini, C; Furrer, H; Ledergerber, B; Cavassini, M; Hirschel, B; Vernazza, P; Bernasconi, E; Weber, R; Battegay, M (2010). Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Archives of Internal Medicine, 170(1):57-65.

Lodwick, R; Costagliola, D; Reiss, P; Torti, C; Teira, R; Dorrucci, M; Ledergerber, B; Mocroft, A; Podzamczer, D; Cozzi-Lepri, A; Obel, N; Masquelier, B; Staszewski, S; García, F; De Wit, S; Castagna, A; Antinori, A; Judd, A; Ghosn, J; Touloumi, G; Mussini, C; Duval, X; Ramos, J; Meyer, L; Warsawski, J; Thorne, C; Masip, J; Pérez-Hoyos, S; Pillay, D; van Sighem, A; Lo Caputo, S; Günthard, H; Paredes, R; De Luca, A; Paraskevis, D; Fabre-Colin, C; Kjaer, J; Chêne, G; Lundgren, J D; Phillips, A N (2010). Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Archives of Internal Medicine, 170(5):410-419.

Flammer, A J; Vo, N T T; Ledergerber, B; Hermann, F; Gämperli, A; Huttner, A; Evison, J; Baumgartner, I; Cavassini, M; Hayoz, D; Quitzau, K; Hersberger, M; Sudano, I; Ruschitzka, F; Lüscher, T F; Noll, G; Weber, R (2009). Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomized controlled trial. Heart, 95(5):385-390.

Müller, V; von Wyl, V; Yerly, S; Böni, J; Klimkait, T; Bürgisser, P; Ledergerber, B; Günthard, H F; Bonhoeffer, S (2009). African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study. AIDS, 23(10):1269-1276.

Kovari, H; Ledergerber, B; Peter, U; Flepp, M; Jost, J; Schmid, P; Calmy, A; Mueller, N J; Muellhaupt, B; Weber, R (2009). Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clinical Infectious Diseases, 49(4):626-635.

Fellay, J; Ge, D; Shianna, K V; Colombo, S; Ledergerber, B; Cirulli, E T; Urban, T J; Zhang, K; Gumbs, C E; Smith, J P; Castagna, A; Cozzi-Lepri, A; De Luca, A; Easterbrook, P; Günthard, H F; Mallal, S; Mussini, C; Dalmau, J; Martinez-Picado, J; Miro, J M; Obel, N; Wolinsky, S M; Martinson, J J; Detels, R; Margolick, J B; Jacobson, L P; Descombes, P; Antonarakis, S E; Beckmann, J S; O'Brien, S J; Letvin, N L; McMichael, A J; Haynes, B F; Carrington, M; Feng, S; Telenti, A; Goldstein, D B (2009). Common genetic variation and the control of HIV-1 in humans. PLoS Genetics, 5(12):e1000791.

Rotger, M; Bayard, C; Taffé, P; Martinez, R; Cavassini, M; Bernasconi, E; Battegay, M; Hirschel, B; Furrer, H; Witteck, A; Weber, R; Ledergerber, B; Telenti, A; Tarr, P E (2009). Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. Circulation: Cardiovascular Genetics, 2(6):621-628.

Peters, L; Mocroft, A; Soriano, V; Rockstroh, J K; Losso, M; Valerio, L; Aldins, P; Reiss, P; Ledergerber, B; Lundgren, J D (2009). Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. JAIDS Journal of Acquired Immune Deficiency Syndromes, 50(5):457-463.

Combescure, C; Vallier, N; Ledergerber, B; Cavassini, M; Furrer, H; Rauch, A; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B (2009). How reliable is an undetectable viral load? HIV Medicine, 10(8):470-476.

Ballif, M; Ledergerber, B; Battegay, M; Cavassini, M; Bernasconi, E; Schmid, P; Hirschel, B; Furrer, H; Rickenbach, M; Opravil, M; Weber, R (2009). Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. PLoS ONE, 4(12):e8275.

von Wyl, V; Yerli, S; Böni, J; Bürgisser, P; Klimkait, T; Battegay, M; Bernasconi, E; Cavassini, M; Furrer, H; Hirschel, B; Vernazza, P; Francioli, P; Bonhoeffer, S; Ledergerber, B; Günthard, H (2009). Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clinical Infectious Diseases, 48(7):979-987.

Scherrer, A U; Hasse, B; von Wyl, V; Yerly, S; Böni, J; Bürgisser, P; Klimkait, T; Bucher, H C; Ledergerber, B; Günthard, H F (2009). Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS). HIV Medicine, 10(10):647-656.

Sterne, J A C; May, M; Costagliola, D; de Wolf, F; Phillips, A N; Harris, R; Funk, M J; Geskus, R B; Gill, J; Dabis, F; Miró, J M; Justice, A C; Ledergerber, B; Fätkenheuer, G; Hogg, R S; Monforte, A D; Saag, M; Smith, C; Staszewski, Sc; Egger, M; Cole, S R (2009). Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet, 373(9672):1352-1363.

Weber, R; Huber, M; Rickenbach, M; Furrer, H; Elzi, L; Hirschel, B; Cavassini, M; Bernasconi, E; Schmid, P; Ledergerber, B (2009). Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. HIV Medicine, 10(7):407-416.

Kuster, S P; Ruef, C; Ledergerber, B; Hintermann, A; Deplazes, C; Neuber, L; Weber, R (2008). Quantitative antibiotic use in hospitals: Comparison of measurements, literature review, and recommendations for a standard of reporting. Infection, 36(6):549-559.

Kuster, S P; Ruef, C; Zbinden, R; Gottschalk, J; Ledergerber, B; Neuber, L; Weber, R (2008). Stratification of cumulative antibiograms in hospitals for hospital unit, specimen type, isolate sequence and duration of hospital stay. Journal of Antimicrobial Chemotherapy, 62(6):1451-1461.

Clifford, G M; Rickenbach, M; Polesel, J; Dal Maso, L; Steffen, I; Ledergerber, B; Rauch, A; Probst-Hensch, N M; Bouchardy, C; Levi, F; Franceschi, S (2008). Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS, 22(16):2135-2141.

Kuster, S P; Ruef, C; Bollinger, A K; Ledergerber, B; Hintermann, A; Deplazes, C; Neuber, L; Weber, R (2008). Correlation between case mix index and antibiotic use in hospitals. Journal of Antimicrobial Chemotherapy, 62(4):837-842.

Keiser, O; Orrell, C; Egger, M; Wood, R; Brinkhof, M W G; Furrer, H; van Cutsem, G; Ledergerber, B; Boulle, A (2008). Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Medicine, 5(7):e148.

Vo, N T T; Ledergerber, B; Keiser, O; Hirschel, B; Furrer, H; Battegay, M; Cavassini, M; Bernasconi, E; Vernazza, P; Weber, R (2008). Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 197(12):1685-1694.

HIV Cohort Study, Switzerland; von Wyl, V; Yerly, S; Klimkait, T; Böni, J; Bürgisser, P; Battegay, M; Bernasconi, E; Cavassini, M; Furrer, H; Hirschel, B; Vernazza, P L; Rickenbach, M; Ledergerber, B; Guenthard, H F (2008). Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clinical Infectious Diseases, 46:1299-1309.

Berger, S; Schad, T; von Wyl, V; Ehlert, Ulrike; Zellweger, C; Furrer, H; Regli, D; Ledergerber, B; Battegay, M; Weber, R; Gaab, J; Vernazza, P (2008). Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. AIDS, 22(6):767-775.

Weiser, B; Philpott, S; Klimkait, T; Burger, H; Kitchen, C; Bürgisser, P; Gorgievski, M; Perrin, L; Piffaretti, J C; Ledergerber, B (2008). HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy. AIDS, 22(4):469-479.

Ledergerber, B; Eichler, K (2008). Datenmanagement. In: Bachmann, L M; Puhan, M A; Steurer, J. Patientenorientierte Forschung : Einführung in die Planung und Durchführung einer Studie. Bern: Huber Verlag, 47-60.

Kuller, L H; Tracy, R; Belloso, W; De Wit, S; Drummond, F; Lane, H C; Ledergerber, B; Lundgren, J; Neuhaus, J; Nixon, D; Paton, N I; Neaton, J D; INSIGHT SMART Study Group (2008). Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Medicine, 5(10):e203.

Soriano, V; Mocroft, A; Rockstroh, J; Ledergerber, B; Knysz, B; Chaplinskas, S; Peters, L; Karlsson, A; Katlama, C; Toro, C; Kupfer, B; Vogel, M; Lundgren, J; EuroSIDA Study, Group (2008). Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. Journal of Infectious Diseases, 198(9):1337-1344.

Yerly, S; von Wyl, V; Ledergerber, B; Böni, J; Schüpbach, J; Bürgisser, P; Klimkait, T; Rickenbach, M; Kaiser, L; Günthard, H F; Perrin, L (2007). Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS, 21(16):2223-2229.

von Wyl, V; Yerly, S; Böni, J; Bürgisser, P; Klimkait, T; Battegay, M; Furrer, H; Telenti, A; Hirschel, B; Vernazza, P L; Bernasconi, E; Rickenbach, M; Perrin, L; Ledergerber, B; Günthard, H F; Swiss HIV Cohort Study (2007). Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Archives of Internal Medicine, 167(16):1782-1790.

Sendi, P; Günthard, H F; Simcock, M; Ledergerber, B; Schüpbach, J; Battegay, M (2007). Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure. PLoS ONE, 2(1):e173.

Franceschi, S; Polesel, J; Rickenbach, M; Dal Maso, L; Probst-Hensch, N M; Fux, C; Cavassini, M; Hasse, B; Kofler, A; Ledergerber, B; Erb, P; Clifford, G M (2006). Hepatitis C virus and non-Hodgkin's lymphoma: Findings from the Swiss HIV Cohort Study. British Journal of Cancer, 95(11):1598-1602.

Simcock, M; Sendi, P; Ledergerber, B; Keller, T; Schüpbach, J; Battegay, M; Günthard, H F (2006). A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off? Antiviral Therapy, 11(3):305-314.

Lowy, A; Page, Julie; Jaccard, R; Ledergerber, B; Somaini, Bertino; Weber, R; Szucs, Thomas D (2005). Costs of treatment of Swiss patients with HIV on antiretroviral therapy in hospital-based and general practice-based care: a prospective cohort study. AIDS Care, 17(6):698-710.

Haupts, S; Ledergerber, B; Böni, J; Schüpbach, J; Kronenberg, A; Opravil, M; Flepp, M; Speck, R F; Grube, C; Rentsch, K; Weber, R; Günthard, H F (2003). Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Antiviral Therapy, 8(5):443-454.

Schüpbach, J; Böni, J; Bisset, L R; Tomasik, Z; Fischer, M; Günthard, H F; Ledergerber, B; Opravil, M (2003). HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes, 33(3):292-299.

Schüpbach, J; Tomasik, Z; Nadal, D; Ledergerber, B; Flepp, M; Opravil, M; Böni, J (2000). Use of HIV-1 p24 as a sensitive, precise and inexpensive marker for infection, disease progression and treatment failure. International Journal of Antimicrobial Agents, 16(4):441-445.

Ledergerber, B; Flepp, M; Böni, J; Tomasik, Z; Cone, R W; Lüthy, R; Schüpbach, J (2000). Human immunodeficiency virus type 1 p24 concentration measured by boosted ELISA of heat-denatured plasma correlates with decline in CD4 cells, progression to AIDS, and survival: comparison with viral RNA measurement. Journal of Infectious Diseases, 181(4):1280-1288.

Schmid, Margrit; Twisselmann, Wiebke; Jacquat, B J; Ledergerber, B; Battegay, M; Egger, M (1996). Geschlechtsunterschiede im Krankheitsverlauf: Analyse der schweizerischen HIV-Kohortenstudie. Swiss Medical Weekly, 126(51-52):2234-2236.

Opravil, M; Weber, R; Ledergerber, B; Speich, R; Siegenthaler, W; Lüthy, R (1990). Compliance and laboratory data predict relapse rate of Pneumocystis carinii pneumonia during prophylaxis with aerosol pentamidine. Klinische Wochenschrift, 68(8):397-402.

This list was generated on Tue Jul 25 14:35:01 2017 CEST.